What is Insulin Detemir?

A long-acting basal insulin analog sold as Levemir.

Insulin Detemir in the library · · Human Trials · What are peptides?

206 registered trials · 203 indexed papers · 235 human / 1 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A long-acting basal insulin analog sold as Levemir.

Type: Long-acting insulin analog.

Definition (National Library of Medicine)

“A recombinant long-acting insulin and hypoglycemic agent in which a myristic acid is conjugated to a lysine at position b29. It is used to manage blood glucose levels in patients with diabetes mellitus.”

MeSH: Insulin Detemir

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Insulin Detemir is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (206)

Trial	Phase	Status	Year	Enrolled
A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes	Phase 1	completed	2024	117
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)		recruiting	2024	430
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes		recruiting	2024	430
DETERMINE: Detemir vs NPH	Phase 2	recruiting	2022	336
Afrezza® INHALE-1 Study in Pediatrics	Phase 3	completed	2021	319
A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works	Phase 1	completed	2021	30
Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM		unknown	2021	40
Oral Anti Diabetic Agents in the Hospital	Phase 4	terminated	2020	85
A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine		completed	2019	12847
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy	Phase 4	completed	2018	108
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes	Phase 3	completed	2017	225
Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell		unknown	2017	135
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?		completed	2016	22
MeDiGes Study: Metformine Use in Gestational Diabetes	Phase 3	unknown	2016	200
Sitagliptin in Non-Diabetic Patients Undergoing General Surgery	Phase 4	completed	2016	80
Effects of Intranasal Insulin Administration on Tissue Specific Insulin Sensitivity		completed	2016	10
Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog	Phase 4	terminated	2016	2
Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes	Phase 4	withdrawn	2016
The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients	Phase 2/Phase 3	terminated	2015	65
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes	Phase 3	completed	2015	26
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin	Phase 4	completed	2015	609
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin	Phase 4	completed	2015	705
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)	Phase 4	completed	2015	3304
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study	Phase 4	completed	2014	157
Evaluation of Glycemic Changes During Exercise in Children With Type 1 Diabetes		completed	2014	24
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin	Phase 3	terminated	2014	42
Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors		completed	2014	8
Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM		completed	2014	10
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry		completed	2013	2446
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes	Phase 3	completed	2013	1290
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus	Phase 3	completed	2013	362
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).	Phase 3	completed	2013	621
Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients	Phase 4	completed	2013	181
Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy		completed	2013	105
A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)	Phase 4	completed	2013	46
Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes	Phase 4	terminated	2012	14
Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake		completed	2012	30
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus	Phase 3	completed	2012	350
Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis	Phase 3	completed	2012	19
Insulin Detemir in Obesity Management		active not recruiting	2011	240

Peer-reviewed studies (203)

Paper	Authors	Journal	Year	Type
Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus	Wang H et al.	Journal of drug targeting	2025	Randomized Controlled Trial
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial	Mathiesen ER et al.	The lancet. Diabetes & endocrinology	2023	Randomized Controlled Trial
Comparison of two titration programmes for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus	Liu SC et al.	Diabetes, obesity & metabolism	2023	Randomized Controlled Trial
Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial	Fishel Bartal M et al.	American journal of obstetrics and gynecology	2021	Randomized Controlled Trial
Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk	Huang WC et al.	Scientific reports	2021	Observational Study
Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study	Ji J et al.	BMJ open diabetes research & care	2020	Randomized Controlled Trial
Comparison of the Efficacy and Safety of Insulin Detemir Administered Once Daily According to Two Titration Algorithms (3-0-3 and 2-4-6-8) in Patients with Type 2 Diabetes Mellitus	Yu HM et al.	Endocrinology and metabolism (Seoul, Korea)	2020	Randomized Controlled Trial
Comparison of Hypoglycemia and Safety Outcomes With Long-Acting Insulins Versus Insulin NPH in Pregestational and Gestational Diabetes	Sleeman A et al.	The Annals of pharmacotherapy	2020	Observational Study
Determining the effects of insulin Detemir on endogenous secretion of insulin	Klenner JB et al.	Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference	2019	Clinical Trial
Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK	Thalange N et al.	BMJ open diabetes research & care	2019	Randomized Controlled Trial
Comparison between the effect of regular human insulin and NPH with novo-rapid and levemir insulin in glycemic control in gestational diabetes	Amini FG et al.	Human antibodies	2019	Randomized Controlled Trial
A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study	Abreu M et al.	Diabetes, obesity & metabolism	2019	Randomized Controlled Trial
Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study	Lualdi C et al.	Journal of endocrinological investigation	2019	Observational Study
Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial	Bilz S et al.	PloS one	2018	Randomized Controlled Trial
Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes	Mather KJ et al.	The Journal of clinical endocrinology and metabolism	2018	Randomized Controlled Trial
A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2)	Wheeler MD et al.	European journal of pediatrics	2018	Randomized Controlled Trial
Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes	Lipska KJ et al.	JAMA	2018	Observational Study
Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial	Mathieu C et al.	Diabetes, obesity & metabolism	2018	Randomized Controlled Trial
Effects of insulin analogs as an add-on to metformin on cutaneous microcirculation in type 2 diabetic patients	Fysekidis M et al.	Microvascular research	2018	Randomized Controlled Trial
Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors	Zhang T et al.	Diabetes technology & therapeutics	2017	Observational Study
Adiponectin, Leptin, and Leptin Receptor in Obese Patients with Type 2 Diabetes Treated with Insulin Detemir	Olczyk P et al.	Molecules (Basel, Switzerland)	2017	Clinical Trial
Do glycoalbumin levels preferentially reflect changes in postprandial glucose excursions?	Paul SK et al.	Diabetic medicine : a journal of the British Diabetic Association	2017	Randomized Controlled Trial
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)	Russell-Jones D et al.	Diabetes care	2017	Randomized Controlled Trial
Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3)	Rodbard HW et al.	Diabetes, obesity & metabolism	2017	Randomized Controlled Trial
Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus	Chang YH et al.	Acta diabetologica	2017	Clinical Trial
An additional bolus of rapid-acting insulin to normalise postprandial cardiovascular risk factors following a high-carbohydrate high-fat meal in patients with type 1 diabetes: A randomised controlled trial	Campbell MD et al.	Diabetes & vascular disease research	2017	Randomized Controlled Trial
Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study	Takahashi H et al.	Expert opinion on pharmacotherapy	2017	Randomized Controlled Trial
Comparative effectiveness and safety of different basal insulins in a real-world setting	Ji L et al.	Diabetes, obesity & metabolism	2017	Observational Study
Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup	Echtay A et al.	Ethnicity & disease	2017	Observational Study
Prediction of excessive weight gain in insulin treated patients with type 2 diabetes	Cichosz SL et al.	Journal of diabetes	2017	Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Insulin Detemir?

A long-acting basal insulin analog sold as Levemir.

How many registered human trials study Insulin Detemir?

The PeptideWhiz trial index lists 206 registered trials for Insulin Detemir, the most recent from 2024.

How much published research exists on Insulin Detemir?

The PeptideWhiz paper index links 203 PubMed papers to Insulin Detemir; by study type, 235 human and 1 animal studies.

Which conditions is Insulin Detemir researched for?

Atherosclerosis, cardiovascular disease & high blood pressure, Cognition, focus & brain performance, Delayed gastric emptying on GLP-1 medicines, Dementia, Alzheimer's & cognitive decline, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, High cholesterol and statins, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Lung health, asthma & COPD, Post-surgical inflammation and surgery recovery, Pregnancy and breastfeeding: safety notes.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research